Find a trial Find a Pfizer clinical trial Refine your searchSearch Show filtersFilter byLocationPediatric Trials: 0-17 YearsAdult Trials: 18+ YearsAge (years)Sex Sex- Any -MaleFemaleBothMaleFemaleTrial status Indicates the current stage of a clinical study and whether it is or will be open for enrollment or in currently active and enrolling in the near future.Distance (miles)50100150200250+250+Travel DistanceAll0-50 miles0-100 miles0-150 miles0-200 miles1000Find a trialSearching for Matching Trials ...6 trials found for LeukemiaEmailPrint All (6) Recruiting (4) Not yet recruiting (2)Save searchSaved trialsLymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell LymphomaA Clinical Trial to Learn About the Study Medicine (Called TTI-622) Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (MM) NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT03530683RecruitingMale or Female18+ years72study location(s) A Clinical Trial to Learn About the Study Medicine (Called TTI-622) Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma (MM)RecruitingAcute Myeloid LeukemiaCombination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT04385290RecruitingMale or Female18-75years12study location(s) Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)RecruitingAcute Myeloid Leukemia, Acute Lymphoid LeukemiaLatin American Real-world Study in Acute Leukemia NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT05166135RecruitingMale or Female18-99years1study location(s) Latin American Real-world Study in Acute LeukemiaRecruitingChronic Myelogenous LeukemiaSafety And Efficacy Of Bosutinib NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT02501330RecruitingMale or Female1study location(s) Safety And Efficacy Of BosutinibRecruitingAcute Myeloid LeukemiaPost Marketing Surveillance (PMS) Study of Mylotarg NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT05189639Jun 30, 2023 - Planned start date (Not yet recruiting)Male or Female19+ years1study location(s) Post Marketing Surveillance (PMS) Study of MylotargAdult Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaA Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment NCT# stands for National Clinical Trial number. This is a unique identification code given to each clinical trial registered on ClinicalTrials.gov. The format is "NCT" followed by an 8-digit number (for example, NCT00000419). Also called the ClinicalTrials.gov identifier. NCT05597085Nov 01, 2022 - Planned start date (Not yet recruiting)Male or Female18-99years1study location(s) A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment Saved trialsContact usFor more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.
